.jpg "Anti-SOX2 Specificity Assay (Array)")
.jpg "SOX2 IHC Human Cervical Carcinoma (SOX2 1791)")
.jpg "SOX2 IHC Human Lung Carcinoma (SOX2 1791)")
.jpg "SOX2 IHC Mouse (SOX2 1791)")
.jpg "SOX2 IHC Mouse Intestine (SOX2 1791)")
.jpg "SOX2 IHC Mouse Stomach (SOX2 1791)")
%20Gel.jpg "Anti-SOX2(SOX2 1791) Gel")
PDF DatasheetHuman Anti-SOX2 Antibody Product Attributes
SOX2 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-SOX2 antibody staining is expected to be primarily localized to the nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in SOX2 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of SOX2 could be seen inrespiratory epithelial cells in the bronchus, glial cells in the cerebral cortex, neuronal cells in the cerebral cortex, squamous epithelial cells in the cervix, uterine and esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, fibroblasts in mesenchymal tissue, germinal center cells in the tonsil and squamous epithelial cells in the vagina. We were unable to detect SOX2 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of SOX2 expression as measured by anti-SOX2 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | + | + | + | – | + | + | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SOX2 Variability | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | + | + | + | + | + | + | + | + | ++ | ++ | ++ |
| SOX2 General Information | |
|---|---|
| Alternate Names | |
| SRY, sex determining region Y-box 2, SOX2, Transcription Factor SOX-2 | |
| Molecular Weight | |
| 34kDa | |
| Chromosomal Location | |
| 3q26.33 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | SOX2 |
| Entrez Gene ID | 6657 |
| Ensemble Gene ID | ENSG00000181449 |
| RefSeq Protein Accession(s) | NP_003097 |
| RefSeq mRNA Accession(s) | NM_003106, |
| RefSeq Genomic Accession(s) | NC_018914, NG_009080, NC_000003 |
| UniProt ID(s) | A0A0U3FYV6, P48431 |
| UniGene ID(s) | A0A0U3FYV6, P48431 |
| HGNC ID(s) | 11195 |
| Cosmic ID(s) | SOX2 |
| KEGG Gene ID(s) | hsa:6657 |
| PharmGKB ID(s) | PA36032 |
| General Description of SOX2. | |
| SOX2 is a member of the SRY-related HMG-box (SOX) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate. At present, 30 Sox genes have been identified. SOX2 is required for stem cell maintenance in the central nervous system, and it also regulates gene expression in the stomach. SOX2 is necessary for regulating multiple transcription factors that affect Oct 3/4 expression. An essential function of SOX2 is to stabilize embryonic stem cells in a pluripotent state by maintaining the requisite level of Oct 3/4 expression. | |
There are no reviews yet.